



CYTORI THERAPEUTICS INC.
Attention: James Vagner
HARMAC MEDICAL PRODUCTS, INC.
2201 BAILEY AVE.
Buffalo, NY 14211
Email Address: (b) (6) @harmac.com

February 9, 2023

Re: BK220699 (Formally K132815)
Trade/Device Name: PUREGRAFT 50 SYSTEM
Regulation Number: 21 CFR 878.5040
Regulation Name: Suction lipoplasty system
Regulatory Class: Class II
Product Code: QKL

Dear Mr. Vagner:

The Food and Drug Administration (FDA) is sending this letter to notify you of an administrative change related to your previous substantial equivalence (SE) determination letter dated January 24, 2014. Specifically, FDA is updating this SE Letter because FDA has assigned your submission a new submission tracking number and created a new product code to better categorize your device technology.

Please update the registration and listing of the device within the FURLS Device Registration and Listing Module according to <http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/RegistrationandListing/ucm053185.htm>.

For more information, please refer to the Federal Register Notice *Consolidation of Devices That Process Autologous Human Cells, Tissues, and Cellular and Tissue-Based Products at the Point of Care To Produce a Therapeutic Article* (86 FR 50887, available at <https://www.federalregister.gov/documents/2021/09/13/2021-18912/consolidation-of-devices-that-process-autologous-human-cells-tissues-and-cellular-and-tissue-based>).

Page 2 – BK220699 – James Vagner

Please note that the 510(k) submission was not re-reviewed. For questions regarding this letter please contact the Regulatory Project Manager, Hosna Keyvan by email at hosna.keyvan@fda.hhs.gov.

Sincerely,

Wilson W. Bryan, MD
Director
Office of Tissues and Advanced Therapies
Center for Biologics Evaluation and Research

Enclosure